Antidepressants are used for long periods of time and until recently there were no formal requirements for establishing efficacy in the maintenance phase or the prophylactic phase of the treatment of depression. The CPMP guidelines advise regulatory authorities in the EEC to consider the efficacy of antidepressants in the medium and the long term separately from efficacy in the treatment of the acute episode. This paper reviews the efficacy of antidepressants in continuation treatment and prophylactic treatment of unipolar depression. Prophylactic studies are difficult and time consuming and it is important to adopt adequate trial methodology. The minimum criteria for the demonstration of prophylactic efficacy are presented.
Introduction
Depression is a very common disorder and it has been estimated that between 20 and 26% of all women and between 8 and 12% of men will develop depression at some time in their lives (Boyd and Weissman, 1981) . The estimates of the proportion of patients who will suffer only a single episode vary widely and probably depend partly on the length of follow-up (Angst 1973; Coryell and Winokur, 1985) . There is, however, general agreement that the majority of unipolar depression is recurrent (Nystrom 1979 ; Zis and Goodwin, 1979) and it is therefore surprising that although the efficacy of antidepressants in treating the acute episodes is well established there are so few studies investigating the efficacy of longer-term treatments.
Clinicians tend to assume that if an antidepressant is effective in the acute illness it will also be effective prophylactically. This assumption would help to explain why some of the most widely used antidepressants in long-term usage have not been adequately investigated for this indication. The recent guidelines of the Committee on Proprietary Medicinal Products (CPMP) of the EEC on the investigation of antidepressant drugs proposes an important new area for establishing the efficacy of antidepressant drugs. It is recommended that efficacy is established in two aspects of long-term treatment; maintenance treatment following the resolution of the acute episode; and prophylaxis to reduce the risk of new episodes. Up to now the antidepressant efficacy of a new compound has been exclusively judged by the ability to ameliorate depressive symptoms in syndromally defined depressive illness over the acute phase of the illness lasting 4-6 weeks. It appears, however, that in spite of a virtual disappearance of symptoms the episode may not be fully resolved and antidepressants should be given beyond the acute phase of the illness. Premature discontinuation of treatment before 4 to 6 months causes a return of symptoms of the inadequately treated depression (Prien and Kupfer, 1986) .
Continuation phase of acute treatment
Amitriptyline The question of the value of continuing therapy with an antidepressant following response of the symptoms in the acute episode has been addressed in a number of placebo-controlled studies. Those on amitriptyline, the most widely studied antidepressant, are small but they show a consistent and significant benefit in reducing relapse 48 during the follow-up period. An early study of electroconvulsive treatment (ECT)-treated patients (Kay, Fahy and Garside, 1970) found a significant advantage for amitriptyline compared with diazepam in a 7 month study. This result is difficult to assess since it is possible that diazepam has a negative rather than a neutral effect. Three subsequent studies (Mindham, Howland and Shepherd, 1973; Klerman et al., 1974; Stein, Rickels and Weise, 1980) compared amitriptyline with placebo and found the former to be associated with significantly less relapses at 6 and 8 months than placebo. The Medical Research Council study of amitriptyline, lithium and placebo (Glen, Johnson and Shepherd, 1984) was inadequately reported. This 3 year study, among its many errors and design flaws, unfortunately reported all relapses in the first 6 months as though they were recurrences of new episodes of depression. The numbers in the study were too small to test efficacy validly, as far as one can tell; three out of seven patients on amitriptyline and five out of nine patients on placebo relapsed in the six months continuation period. These relapse rates, although not significant, are in line with the other studies.
Imipramine
The results with imipramine are less consistent with one study demonstrating efficacy and one failing to demonstrate a significant difference compared with placebo. The Seager and Bird (1962) study showed imipramine to be better than placebo at 6 months, whereas the later study of Mindham, Howland and Shepherd (1973) did not. One further study (Prien, Klett and Caffey, 1973) which lasted 2 years had sufficient morbidity in the first 4 months to provide significant evidence for the role of imipramine and lithium in continuation therapy. The overall consistency of the results in these studies has confirmed clinical experience that antidepressant treatment needs to be continued for some months after apparent response of the acute episode until the episode has resolved.
Length of continuation treatment period
It is important to know how long the continuation treatment period should be, not only so that patients may receive optimum treatment but also to distinguish between relapse of an inadequately treated episode and the occurrence of symptoms of a new episode. Early investigators suggested that the minimum treatment period should coincide with the length of the untreated episode. In spite of the extensive epidemiological data on the duration of illness, our knowledge of the likely length of a particular patient's illness is imprecise. The duration of episodes may lengthen slightly with recurrence (Kielholz, 1959) . Some depressions run a chronic course, and the natural length of an episode would also be difficult to estimate from a patient's history because of intervention with antidepressants.
An examination of when relapse occurred in the placebo-controlled studies of continuation therapy can provide some guidance as to the likely minimum length of treatment. Prien, Flett and Caffey (1973) report a rather high relapse rate of 73% at 4 months treatment with placebo. The data of Mindham, Howland and Shepherd (1973) show that there is a 20% relapse rate on placebo in the first 4 weeks after early discontinuation of antidepressant treatment, and more than 40% in the first 16 weeks. This is generally consistent with the results of Prien and Kupfer (1986) , who retrospectively analysed the relapse rates on placebo following early discontinuation of acute antidepressant treatment in an earlier study (Prien et al., 1984) which continued for 2 years; they report a relatively high overall relapse rate in the first 16 weeks (44%), the highest rate occurring in the first 8 weeks (38%).
It could of course be argued that these relapses associated with placebo early in the continuation phase of treatment are in fact new episodes of depression, but an examination of the relapse rates in relation to the expected rate of recurrence of new episodes makes this seem unlikely. If the relapse rate represented early recurrence one would expect a high rate in recurrent depression and a lower relapse rate in a group of first time depressions since this would be more likely to include patients who may only have a single episode of depression. In the study of Mindham, Howland and Shepherd (1973) the relapse rate on placebo was 46% in those 30 patients with no previous history of depression. In their study, and in other studies, the relapse rates in those with or without a history of previous episodes of depression are similar. The epidemiological data suggest that even if all first episode depressions were assumed to be recurrent the proportion who would be expected to have a new episode so soon would be far less than the rate of relapse seen. The data indicate that the relapse rates are not related to the number of previous recurrences, and it is difficult therefore to regard the relapses on early discontinuation of treatment as new episodes of depression since they occur so much earlier than the natural history would suggest. It is more likely that these relapses are part of the previous inadequately treated depression.
There have been a number of suggestions as to the necessary length of the continuation treatment period. Coppen et al. (1971) proposed 4 months, a suggestion which has been supported by Prien, Klett and Caffey (1973) and Bjork (1983) . Prien and Kupfer (1986) and Montgomery et al. (1988) suggest a period of 4-5 months and Klerman and Paykel (1970) and Mindham, Howland and Shepherd (1973) suggest 6 months. The consensus emerging from these studies is that all treatment courses should continue for at least 4 months after response, and that all relapses before that point after early discontinuation should be regarded as part of the original illness rather than the occurrence of a new episode. Between 4 and 6 months the re-emergence of symptoms will represent relapses of the original episode in a decreasing proportion of instances and the number of doubtful cases should be small.
Minimum criteria for prophylactic studies
The distinction between relapse and recurrence is of primary importance in assessing prophylactic efficacy. Prophylaxis is a quite different aspect of the possible efficacy of an antidepressant and reflects its ability to reduce the likelihood of a new episode of depression occurring. The knowledge of the research methodology needed to demonstrate prophylactic efficacy is not widely understood; it may therefore be helpful to review some commonly made errors of trial design and to discuss the minimum criteria that need to be adopted for a study to test the effectiveness of an agent in reducing the risk of a new depressive episode.
Symptom-free period
In order to establish efficacy it is obvious that the patient should have fully recovered from the previous episode of depression. As the studies of continuation treatment have shown, response of the acute episode cannot be relied upon as an indicator that the episode is fully resolved. It is necessary to ensure that the depression has been adequately treated, and that the patient remained well during maintenance treatment beyond the period when relapse of symptoms of the episode would be expected on discontinuation. For the purposes of the prophylactic study a defined symptom-free period is necessary before the assessment of prophylaxis can begin. Unless patients have been symptom-free for a sufficient period before entering a prophylactic study it is not possible to say whether a relapse represents the reappearance of symptoms of the original episode or the occurrence of a new episode. Surprisingly few studies which purport to measure prophylaxis satisfy this simple criterion. Varying lengths of symptom-free periods have been adopted in different studies but the evidence from the continuation treatment studies suggests that patients should fulfil a symptomfree period of at least 4 months before prophylaxis can be validly assessed.
Recurrence rate
An important criterion for studies to assess prophylaxis is that the group of patients studied should be expected to have a sufficient number of new episodes of depression in the trial period in order to test efficacy. The epidemiological data indicate that the duration of intervals between episodes tends to decrease with recurrence and age of onset of the first episode, so the cycles of recurrence increase with the number of previous episodes. Some indication of the chance of recurrence expected in the study period may be obtained from the number of previous episodes of depression, and several different criteria have been used. Early studies of prophylaxis using lithium in mixed groups of bipolar and unipolar patients included only patients who had a history of three or more episodes of illness. The single prophylactic study on amitriptyline (Coppen et al., 1978) used a criterion of two or more episodes. More recently a study on fluoxetine used the criterion of a history of two or more episodes, in 5 years ). The number of patients required to test possible efficacy depends largely on the proportion of patients expected to have a new episode of depression in the study period, and a history of either three or two episodes in 5 years; both seem to be adequate indicators of predicted morbidity.
Placebo control
The recurrence rate on any individual patient is not, however, quite so predictable and it is difficult to say whether the absence of a recurrence is because the drug is effective or because the patient would not have had a new episode within the study period. It is only in a study of adequate size using a double-blind group comparison design with a placebo control that it is possible to draw conclusions about the relative recurrence rate on an active compound compared with placebo and make any valid comment about prophylactic efficacy. The CPMP guidelines recommend using a placebo control in testing prophylaxis on the quite obvious grounds that reference tricyclic antidepressants (TCAs) are not sufficiently well studied to be sure of their prophylactic efficacy. The evidence from the number of comparisons of two presumed active drugs adds little to our knowledge, partly because the studies are too small to be able to establish equal efficacy and partly because there is no established reference agent. Reference-controlled studies are less useful because the numbers required to establish equivalent efficacy would be very much larger than the studies carried out up till now. Placebocontrolled studies are at the moment the only practical and scientifically valid means of establishing prophylactic efficacy. Adequate size of study It is important that sufficient numbers of patients are included so that the predicted morbidity is sufficient to provide a fair test of the prophylactic ability of the antidepressant. Prophylactic studies are very demanding and time-consuming, and all too often this effort is wasted because too few patients were included to make any valid comment on efficacy. It is not ethical to ask patients to participate in a study which is incapable of answering the intended question. The calculation of the number of patients needed in a study of acute efficacy in depression is based on both the expected placebo and the expected active compound responses and there are sufficient studies in the literature to gain an adequate estimate of both.
Response measures
The clearest measure of prophylactic efficacy is the ability of the agent to reduce the recurrence rate of new episodes compared with placebo and all studies should report on this. It should also be remembered that the severity of the original episode may have an effect on treatment outcome (Prien et al., 1984) , and it is helpful if the analysis takes account of this possibility. Prophylactic agents may, however, also prolong the period before recurrence, and analyses using life table and regression models would take this into account. The two variables are often but not necessarily linked, and it is possible that a treatment may prolong the well period or that it may mask the emerging recurrence without reducing the recurrence rate.
It is also possible that an effective prophylactic treatment will reduce the severity of the subsequent depressive episode and this may be taken into account by examining the severity of depression at recurrence in the treatment groups. The affective morbidity index (Coppen et al., 1971 ), widely used in lithium studies, is not appropriate in studies of new antidepressants in unipolar depression as it measures a more complex, possibly synergistic interaction between the prophylactic agent and the antidepressant treatment used for the newly arising episode. Analysis is further complicated by the lack of distinction between the continuation and prophylactic phases following a new episode arising during the study.
The analysis of prophylactic studies should be performed on those patients who complete the study, but this analysis should be complemented by an analysis of all patients included on an intention-to-treat basis. The advantage of the second analysis is that it gives some measure of the acceptability of the treatment in long-term use and the dropouts due to all factors.
Duration of prophylactic studies
The choice of duration of a prophylactic study is determined by whether prophylactic efficacy can be demonstrated or not. The longer the study period, the more recurrences would be expected and the more likely prophylactic efficacy may be tested. Unfortunately, in long studies lack of compliance and dropouts may well compromise the ability to test efficacy. There are strong practical and ethical reasons for choosing the shortest possible period to test prophylactic efficacy compared with placebo. The CPMP guidelines recommend a 1-2 year study period, but it now appears likely that with larger numbers and bet-ter methodology this may be rather longer than is strictly necessary.
Prophylactic studies with tricyclic antidepressants (TCAs) Amitriptyline studies Very few studies of prophylaxis with antidepressants satisfy these simple criteria. Amitriptyline has been found to be effective in the only study of its prophylactic efficacy which meets these criteria (Coppen et al., 1978) . This study was, however, relatively small compared with later studies (36 patients) and used a short minimum symptom-free period of 6 weeks before entry into the prophylactic phase. The report of the Medical Research Council (MRC) study (Glen, Johnson and Shepherd, 1984) of the prophylactic effect of amitriptyline is misleading.
No valid conclusion should be drawn from the results of four patients each on amitriptyline or placebo who survived the 6 months continuation phase and entered the 22 year prophylactic part of the study.
Imipramine studies Imipramine has been found to be effective in two studies. The first study (Prien, Klett and Caffey, 1973) did not have a defined symptom-free period, but an analysis of survivors after the 4 month continuation period showed that both imipramine and lithium were effective compared with placebo. Imipramine was also found to be superior to placebo in the second study of Prien et al. (1984) , which had a short symptom-free period of 2 months prior to entry, but not in another small study (Kane et al., 1982) which, although it meets most of the criteria, was too small to allow valid conclusions. A preliminary analysis of a large placebo-controlled prophylactic study of imipramine still in progress suggests that the case for the prophylactic efficacy of imipramine may well be strengthened when the study is complete (Frank, personal communication).
Lithium studies
The case for the prophylactic efficacy of tricyclic antidepressants is not sufficiently strong to support their use as an active reference control. In bipolar illness lithium has been established as a reference treatment. However, in unipolar depression lithium has been found to be no different from placebo in one study (Prien et al., 1984) , and effective both in the earlier study (Prien et al., 1973) and in the analysis of unipolar patients included in a number of studies made by Schou (1979) . Many clinicians have found that tricyclic antidepressants (TCAs) and lithium are indeed effective as prophylactic agents in unipolar depression on the basis of their experience in the clinic. Unfortunately, there have been too few adequately designed studies to establish these drugs as reference prophylactic agents.
Prophylactic studies with 5-HT uptake inhibitors Fluoxetine, zimelidine and sertraline In contrast to the rather patchy evidence for tricyclic antidepressants the case for the prophylactic efficacy of the newer 5-HT uptake inhibitors is consistent and the efficacy is more confidently established. The large, recently published, study of fluoxetine found a significant effect at 3 months, and highly significant prophylactic efficacy compared with placebo at 6, 9 and 12 months . This study satisfies the minimum design criteria: it had a 42 month symptom-free period; the definition of recurrence used of two episodes in 5 years was adequate; and the size of the study with 220 patients entering was sufficient to be confident of the result. The clearcut result with fluoxetine is the strongest finding of prophylactic efficacy for an antidepressant yet published. Bjork (1983) found zimelidine to be effective as a prophylactic agent in a small placebo-controlled study of 38 unipolar patients. This 18 month study was well designed with a 4 month symptom-free period prior to entry, and the group of patients studied had a sufficient recurrence rate to be able to test prophylactic efficacy. The importance of this finding was lost largely because zimelidine had been withdrawn by the time the paper was published. The report of the effectiveness of sertraline in preventing relapse over a 44 week continuation study is interesting (Doogan and Caillard, 1988 ). The main result shows efficacy in maintenance treatment, but the size of the study is just large enough to allow an analysis of those patients surviving in the study beyond the 4 month point, after which prophylaxis may be measured. This analysis suggests prophylactic efficacy for sertraline (Montgomery, 1988) .
The confidence in the result with fluoxetine, and the consistency of findings with other 5-HT uptake inhibitors so far tested, suggest that 5-HT uptake inhibitors may indeed have a special role in prophylaxis in unipolar depression. One should, however, be cautious in making relative judgements of the prophylactic ability of different antidepressants on the basis of results from relatively early and flawed studies of tricyclic antidepressants compared with results from the more stringent methodology and larger numbers used in the studies of the 5-HT uptake inhibitors. It is possible that reference tricyclic antidepressants might have shown similar prophylactic effects if they had been subjected to the same rigorous study. The results with the 5-HT uptake inhibitors are welcome because they greatly strengthen the case for prophylaxis in recurrent unipolar depression.
Dosage
Clinicians are inclined to use a lower dose for prophylaxis than has been used in the acute treatment phase. However, when one examines the evidence, the studies that have found prophylactic efficacy have mainly used doses shown to be effective in acute treatment. The main reason for using a lower dose with the tricyclic antidepressants is because of the unpleasant sideeffects which compromise compliance in the longer term. Side-effects are less of a problem with the newer drugs and poor compliance is less likely. The evidence from existing prophylactic studies suggests the use of a dose shown to be effective in acute treatment. It is entirely possible that a lower dose is effective, but caution dictates using the dose shown to be effective until such time as the lower doses have been properly tested. The correct dose for acute treatment has itself not been adequately investigated for some of the older antidepressants which were introduced before the more stringent requirements of assessment currently in use.
How long should prophylactic treatment continue?
In studies that continued for longer periods of 1-2 years there is no apparent loss of efficacy of the active agent in the later part of the study, although the power of the test is diminished by the reduction in patient numbers. If the prophylactic agent were merely delaying the recognition of the depression rather than eliminating the episodes in some patients, an increased number of recurrences during treatment with the prophylactic agent would be expected late in the study. All the studies show the opposite effect; recurrences during effective treatment tend to tail off in the second part of the study. The implication is that if prophylaxis is effective in an individual over a 1 year trial period treatment should be continued.
The epidemiological data suggests that recurrence increases rather than decreases over time (Angst and Weis, 1967) . The recurrence rate of new depressive episodes in the recurrent unipolar depression group is high (up to 80% in 1 year in patients treated with placebo). The risk of recurrence of new episodes in the studies examined, taking dropouts and recurrences into account, appears to remain high throughout the study period. Data from the more comprehensive studies suggest that after a 2 year period only 15-20% of patients treated with placebo will not have relapsed which makes it very difficult to draw valid conclusions from the studies beyond this period. It is likely that patients with a history of recurrence admitted to prophylactic studies will continue to be at risk of recurrence after the study has finished. For this group of patients it seems that prophylactic treatment should be continued for as long as is necessary, which is likely to be over many years, if not for life. In practice, many patients and clinicians attempt to do without medication after a period of 5 years' successful prophylaxis, and only restart prophylaxis after the re-emergence of symptoms.
An otherwise effective prophylactic agent appears to be ineffective in a proportion of patients whose depression recurs in spite of prophylactic treatment. However, the possibility should not be overlooked that the recurrence might have occurred even earlier without prophylactic treatment. The prophylactic studies reported to date cannot provide a definite answer on this point. In such cases it is worth considering changing to an alternate proven prophylactic agent.
Comment
If patients with recurrent depression are to be exposed to treatment with antidepressants for many years we should be confident of long-term efficacy and safety. The requirement in the CPMP guidelines that maintenance treatment and prophylaxis are demonstrated rather than assumed is therefore welcome. It is not enough to assume that treatments shown to be effective in acute depression also have prophylactic efficacy in reducing the chance of a new episode. It is quite possible to test whether an antidepressant has prophylactic efficacy if the appropriate trial design is adopted, and it is surprising that some of the most widely used antidepressants have not yet been formally tested. The demonstration of prophylactic efficacy is a useful extra test of the antidepressant effect of a compound and clinicians should be aware of the importance of this dimension of treatment.
The evidence suggests that clinicians need to encourage patients to continue with treatment after the acute episode has passed and all patients should continue their antidepressants for a minimum of 4 months after the symptoms have resolved. Those patients with recurrent depression should be offered the opportunity of reducing the recurrence rate of this dangerous and unpleasant illness by treatment with established prophylactic agents.
